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Medicine (FADOI), theMEDICAL group produced practical management algorithms for patients in internal med-
icine wards.
Methods: TheMEDICAL group panel, composed of 30members from internalmedicine, infectious disease, clinical
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Results: Seven clinical scenarios were constructed based on clinical severity and probability of invasive candidi-
asis. For each scenario, the appropriateness of 63 different diagnostic, imaging, management, or therapeutic pro-
cedures was determined in two Delphi rounds. The necessity for performing each appropriate procedure, was
then determined in a third Delphi round. Results were summarized in algorithms.
Discussion: The proposed algorithms provide internal medicine physicians and managers with an easy to inter-
pret tool that is exhaustive, clear and suitable for adaption to individual local settings. Attention was paid to in-
dividual patient management and resource allocation.
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Keywords:
Invasive candidiasis
Risk stratiﬁcation
Clinical severity
Medical wards1. Introduction
Invasive candidiasis (IC) is increasingly recognized as a frequent
problem among patients hospitalized in internal medicine wards,it, Scientiﬁc Direction, IRCCS,
ia, Italy.
).
cine. Published by Elsevier B.V. All rigowing to the high prevalence of frail patients in this setting. Such pa-
tients often have risk factors, including mucosal or cutaneous barrier
disruptions, invasive procedures, endovascular devices, parenteral nu-
trition, cancer, chronic renal failure, renal transplantation, liver disease,
immunosuppressive treatments for systemic connective tissue diseases,
extensive exposure to broad spectrum antibiotics andmultisite Candida
colonization [1–7].
Moreover, mortality from IC in medical wards is high, often compa-
rable to that in intensive care units (ICUs). In contrast, the level ofhts reserved.
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adequate [8,9]. These epidemiological features have contributed to de-
ﬁning IC as a public health problem with excess mortality, prolonged
hospital stays, and signiﬁcant costs [10].
Despite attention to IC inmedical wards, the evidence-base forman-
agement and treatment is primarily derived from other settings, such as
ICU, transplant units, surgery or hematologywards, andmost guidelines
are directed towards these settings [11,12]. However, patients in medi-
cal wards are often more complex and have more and different comor-
bidities than those “traditionally” studied in earlier experiences on IC. In
our opinion it is not appropriate to directly apply guidelines created for
other settings to the internal medicine setting [13,14].
To address the need for practical guidance on medical patients,
based on imperfect evidence, the Italian Society for Anti-InfectiveTable 1
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Box 2
Selected risk factors for invasive candidiasis
Broad spectrum antibiotic treatment ongoing for at least 5 days
Central venous catheter (CVC) or peripherally inserted central
catheter (PICC)
Parenteral nutrition
Chemotherapy for solid and hematological tumors (including
steroids)
Hospitalization N 10 days in previous 3 months (including nursing
homes/long-term care facilities)
Prior candidemia
Candida colonization in N1 site
Transferred from ICU
Dialysis
Box 3
Definition of invasive candidiasis
Invasive candidiasis (IC) indicates either a deep-seated Candida in-
fection or candidemia. The following categories of diagnostic cer-
tainty were used:
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2.1. Project design, expert panel and literature search
The project was managed by the MEDICAL group, a three-layer (su-
pervisory, steering committee, expert panel), multidisciplinary team,
including experts in infectious diseases and internal medicine, clinical
microbiology, clinical pharmacology, and methodology (Table 1). The
ﬁnal project structure, composition of the expert panel, methods, Au-
thorship criteria, and management of potential conﬂicts of interest
were decided in two preparatory rounds. Expert opinion from the 30-
member panel was elicited through a modiﬁed Delphi process (RAND/
UCLA Method) [18].
The entire process, including preparatory meetings, literature
search, three Delphi rounds, an interimmeeting of the steering commit-
tee and the ﬁnal consensus conference took place between January and
October 2015.
Evidencewas collected by searching the PubMed literature database
with the query terms (candid*[all ﬁelds] OR invasive fungal disease*[all
ﬁelds] OR invasive fungal infection*[all ﬁelds]). In addition, the bibliog-
raphies of retrieved papersweremanually scanned to identify addition-
al evidence. Search results were updated weekly throughout the
project.
2.2. Consensus process
The panel scored the appropriateness of 63 different diagnostic,
imaging, management, or therapeutic procedures in seven clinical sce-
narios. Two scoring rounds were conducted by email. Appropriateness
was scored on a scale of 1 (usually not appropriate) to 9 (always appro-
priate). Terminology for classifying the procedures is presented in Box 1
[19].
The median score and the 30–70 interpercentile range corrected for
asymmetry (IPRAS)were calculated. Procedureswere classiﬁed as inap-
propriate, uncertain, appropriate with disagreement or appropriate
without disagreement. After viewing the results of the ﬁrst round, in
which their own responses were highlighted, panel members were
asked to review their choices in the second round. Then, in a third scor-
ing round, experts rated thenecessity (Box1) of each procedure that had
been classiﬁed “appropriate” without disagreement.
Steering committeemembers drafted separate clinical management
algorithms for sepsis and severe sepsis. The reader is referred to pub-
lished guidelines for treatment of speciﬁc clinical localizations of IC
(e.g., osteomyelitis, endophthalmitis) [20]. At a consensus conference
on October 1–2, 2015, the panel ﬁnalized the algorithms, taking
healthcare costs into consideration, as well as beneﬁts. Consensus was
deﬁned as ≥90% agreement.
2.3. Operational deﬁnitions
Invasive Candida infections are more common in certain popula-
tions, due to the higher incidence of risk factors.We identiﬁed candidateBox 1
Terminology used to describe procedures
- “Could be considered” refers to a procedure that is indicated
only in specific clinical conditions.
- “Appropriate” is used when the overall benefits of the pro-
cedure outweigh harms, and the procedure is recommend-
ed if it is available in the specific clinical setting
- “Necessary“ is usedwhen there is a reasonable chance that
the procedure will benefit the patient, and it would be im-
proper care not to offer it to a patient.risk factors from published studies and risk scores developed and validat-
ed for ICU patients [8,21–27]. 5 days of antibiotic exposure, 10 days prior
hospitalization, and prior candida infectionswere chosen as risk factor for
IC following consensus procedure, based upon literature review and
clinical expertise of participants. Risk factors considered relevant by
≥90% of the panel were included in the analysis (Box 2). Stable clinical
conditions were deﬁned as normal vital signs and no organ failure.
Operational deﬁnitions were adopted also for IC (Box 3), and the
concepts of sepsis, severe sepsis and septic shock [20,28,29]. Persistent
candidemia was deﬁned as isolation of the same Candida species N
72 h after initiation of antifungal therapy [30,31]. Surveillance cultures
were deﬁned as sampling from distinct non-blood body sites in absence
of any clinical indication, performed only to determine colonization sta-
tus. Fundus oculi and echocardiographic evaluations imply serial assess-
ments, because pathological changesmay not be evident in early phases
of IC.2.4. Clinical scenarios
Likelihood of IC was operationally deﬁned as certainty (patients
withmicrobiological diagnosis (blood culture positivity) of IC, high (pa-
tients with two or more risk factors), or low (patients with one risk fac-
tor only). Hypothetical patients were stratiﬁed into one of seven clinical• Proven IC: microbiological evidence of Candida, or yeast
cells, hyphae or pseudohyphae at histology or on direct ex-
amination in a normally sterile tissue or organ
(i.e., excluding urine, sputum, bronchoalveolar lavage, mu-
cous membrane swabs and specimens from skin).
• Probable IC: concomitant presence of an underlying disease
predisposing to IC, two or more risk factors (Box 2), with
signs of active infection [32], and at least one positive anti-
gen test (e.g., beta-D-glucan, mannan/antimannan).
• Possible IC: concomitant presence of an underlying disease
predisposing to IC, one risk factor (Box 2), with signs of ac-
tive infection [32], but without microbiological confirmation.
Table 2
Clinical scenarios based on severity of sepsis and risk factors for invasive candidiasis.
Lower IC probability
1 risk factor
Higher IC probability
2 or more risk factors
Proven IC
Microbiological diagnosis
Asymptomatic Not considered Scenario 1 Not applicable
Sepsis Scenario 2 Scenario 3 Scenario 4 (excluding diagnostic procedures)
Severe sepsis Scenario 5 Scenario 6 Scenario 7 (excluding diagnostic procedures)
Note: septic shock/critically ill patients (with a life-threatening condition, with changes in one or more vital functions – circulation, breathing, mental status – and in need of organ sup-
port) is not within the scope of this consensus.
Fig. 1. Proposed algorithm for the management of a patient with sepsis in internal medicine wards. Procedures deemed necessary in the RAND/UCLA process are required.
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Fig. 2. Proposed algorithm for the management of a patient with severe sepsis in internal medicine wards. Procedures deemed necessary in the RAND/UCLA process are required.
49L. Scudeller et al. / European Journal of Internal Medicine 34 (2016) 45–53scenarios (Table 2), based on both clinical severity (asymptomatic, sepsis
or severe sepsis) (1) and the likelihood of having IC, as deﬁned in Box 3.3. Results
The algorithms are presented according to clinical severity: patients
with sepsis (Fig. 1) or severe sepsis (Fig. 2), eachwith three correspond-
ing scenarios: lower risk of IC, higher risk for IC and proven diagnosis(deﬁned in Box 3). Asymptomatic patients have not been included in
the algorithms; their management is described in Section 3.1.
3.1. Asymptomatic patient with risk factors for IC
Neither therapy nor prophylaxis is recommended for this group of
patients. The primary goal should be to reduce the risks of developing
IC. Multiple colonization is not a risk factor per se, but, because endoge-
nous colonization is the source for themajority of severe episodes of IC,
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toms of IC [33]. The cost/beneﬁt ratio for colonization screening in the
medical setting is not well established and should be discourage.
The indication for peripherally or centrally infused parenteral nutri-
tion in the medical setting should be reassessed frequently in patients
with risk factors for invasive candidiasis [34]. Patients with diabetes or
concomitant C. difﬁcile colitis might have invasive candidiasis without
fever and rarely also without SIRS, patients with these comorbidities
and risk factors for invasive candidiasis should undergo a diagnostic
work-up for invasive candida infections, including non-cultural serolog-
icmethods,where available. The group agrees that there is no indication
for empirical or pre-emptive antifungal treatment in this setting.
3.2. Symptomatic patients
A patient with signs and symptoms of infection must have at least
two blood cultures sets performed, one from a central venous catheter
(CVC), if present. Additional samples from any clinical site suspect for
localization of infection should be tested. In addition, plasma levels of
the C-reactive protein and procalcitonic concentrations should be eval-
uated, despite their low speciﬁcity and sensitivity. Beta-D-glucan (BDG)
has a high negative predictive value, which may help to exclude IC.
However, this test was graded as appropriate but not necessary because
it is not available in all settings. Themannan-antimannan assay can also
be considered, although there is less evidence on the clinical use of this
test. Surveillance cultures may be performed, with the sole aim of
assessing colonization, which is not per se an indication for antifungal
therapy. To date, PCR and other nucleic acid-based tests are not recom-
mended for widespread use at the clinical level.
3.2.1. Non-critically ill patients with sepsis: Algorithm 1 (Fig. 1)
This patient shows signs and symptoms of infection, but is in rela-
tively stable clinical condition. Whereas the causative agent could be
Candida spp., the likelihood of a Candida infection is lower if ≤1 risk fac-
tor is present (scenario 2), and higher if ≥2 risk factors are present (sce-
nario 3). In medical wards, most patients present multiple known risk
factors for IC, thus the “high-risk” scenario is probably more frequent
there. Themanagement goal is correct diagnosis of IC (and its complica-
tions) or its exclusion, and selecting the correct empirical treatment.
3.2.2. Patients without conﬁrmed IC infection
A watchful waiting approach, is appropriate, with re-assessment as
clinically indicated. If antifungal treatment is started, ﬂuconazole is an
acceptable choice, unless there are risk factors for infection with
ﬂuconazole-resistant strains (e.g., previous therapeutic courses of
ﬂuconazole).
If microbiological tests do not lead to a diagnosis of Candida infection
and clinical conditionsdonot improve, then clinical, imaging andmicro-
biological reassessment (with device removal/replacement, if possible)
are appropriate.
3.2.3. Patients with conﬁrmed IC infection
In patientswith a conﬁrmedmicrobiological diagnosis, but relatively
stable clinical condition (scenario 4), the aim of management to select
the correct targeted therapy, reduce the risk of complications or relapse,
and carefully screen for secondary localizations.
Even if the patient is not critically ill, clinicians should administer an-
tifungal therapy as early as possible, preferably an echinocandin. Early
de-escalation to ﬂuconazole is appropriate, if supported by species
identiﬁcation and susceptibility tests. Possible therapeutic alternatives,
depending on the isolated strain and/or local epidemiology, are
ﬂuconazole, voriconazole or a lipid formulation of amphotericin B (LF-
AmB), especially if already started empirically or for other reasons
(e.g., treatment with an echinocandin during the previous 30 days).
Clinical follow-up would necessarily include repeat blood culture
every 48–72 h, device removal and possibly source control if imagingresults reveal a suspected deep infection; an infectious disease clinician
should be consulted. Screening of secondary septic localizations, includ-
ing fundus oculi evaluation, echocardiograph, and ultrasound scan of
neck or arm vessels at the CVC site, are necessary, especially in patients
with persistently positive blood cultures.
3.3. Critically ill patients with severe sepsis: Algorithm 2 (Fig. 2)
This patient shows severe signs and symptoms of infection and is
clinically unstable. The causative agent could be Candida spp.; the prob-
ability is lower if there are ≤1 risk factor (scenario 5), and higher if there
are ≥2 risk factors (scenario 6). As noted above, scenario 5 ismuchmore
frequent in themedicalward, because of patient complexity and comor-
bidities. In patients with severe sepsis, but a low likelihood of IC, the
aims of management are the diagnosis of IC (and its complications)
and selecting the appropriate empiric treatment.
3.3.1. Patients without conﬁrmed IC infection
Imaging studies upon clinical suspicion are indicated for investigat-
ing the source of sepsis. Removal of unnecessary devices is considered
good practice. Infectious disease and intensive care consultations are
necessary, and additional consultations (e.g., surgery, cardiac surgery,
interventional cardiology, vascular surgery) should be sought according
to the clinical picture.
For patients with ≤1 risk factor, it is acceptable to not administer an
antifungal treatment as ﬁrst line therapy, given the low risk of IC in this
scenario. If an antifungal therapy is started, the ﬁrst choice is usually an
echinocandin, with de-escalation to azoles as soon as the patient is clin-
ically stable. Drug interactions should be considered, in particular when
the selected therapy is an azole.
Unstable patientswith ≥2 risk factors require prompt initiation of an
appropriate treatment. In these patients, early antifungal treatment
with an echinocandin is recommended, with de-escalation to an azole
when the patient is clinically stable. An LF-AmB can be a useful option
in some patients.
3.3.2. Patients with conﬁrmed IC infection
In patients with conﬁrmed IC and severe sepsis (scenario 7), the aim
of management is the prompt initiation of adequate therapy, reduction
of risk of complications or relapse, and diagnosis of any secondary
localizations.
In this setting, besides the management recommendations outlined
above for previous scenarios, ﬁrst-line therapy with an echinocandin is
necessary, with an LF-AmB being an alternative. Again, de-escalation to
an azole is appropriate as soon as the patient is clinically stable.
4. Discussion
We propose management algorithms for IC in medical wards,
envisioned as practical assessment and treatment tools. Our proposals
are based on a two-way risk stratiﬁcation strategy that considers both
clinical severity (sepsis vs. severe sepsis) and the likelihood that Candi-
da spp. is a causative agent. We chose a modiﬁed Delphi method
(RAND/UCLA) to identify appropriate and necessary practices in this set-
ting, because formal evidence from controlled clinical trials is lacking.
Using it, we sought to combine the best available scientiﬁc evidence,
also from the ICU setting, and the collective judgment of experts with
extensive experience in managing IC in medical wards.
4.1. IC is common in internal medicine wards
IC in the medical ward setting is understudied and possibly
underestimated, but there is increasing evidence of a rising incidence
[2,3,35]. Also, IC mortality among medical patients appears higher
than in other settings, possibly due to delayed diagnosis, compromised
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that have been elaborated for less complex patients [9,14,32].
The typical patient admitted to a general medical ward is an elderly
subject with multiple comorbidities, including many of the recognized
risk factors for IC [1]. Some IC risk factors are modiﬁable (e.g., prolonged
antibiotic treatment, indwelling devices) and efforts should be made to
avoid exposing frail patients to unnecessary risk,when still asymptomatic
for infection [25,34]. In any scenario, careful reassessment of parenteral
nutrition or ongoing antibiotic therapy should aimatwithdrawingunnec-
essary treatment to avoid these modiﬁable risks for IC (e.g., when the
patient's condition stabilizes). Microbiological diagnosis should be sought
if there is no response after 72–96hof empirical therapy. Surveillance cul-
tures might be useful to identify colonized patients, as often suggested in
ICU patients [36]. Whereas, colonization with Candida spp., per se, is not
an indication for treatment, it should be taken into consideration when
assessing patients who become symptomatic.
4.2. Early diagnosis or exclusion of IC requires proper microbiological
diagnosis
Early diagnosis and treatment of invasive candidiasis are associated
with improved survival [37,38]. Elderly and patients with comorbidities
may have blunted inﬂammatory and febrile response due to impaired
immune function as a direct consequence of advanced age (immune
aging) [39,40] and/or to steroid or other immune suppressive therapy,
including cancer therapy. Other components of the systemic inﬂamma-
tory response syndrome may be lacking, including tachycardia due to
beta-blocker use, tachypnea due to muscle atrophy and hypocapnia
due to chronic respiratory failure. Diabetes mellitus may impair re-
sponse to infections and favor fungal growth. Afebrile patients with
candidemia have been described [41], and in one study, up to 20% of pa-
tients with candidemia did not show SIRS criteria [42]. In the absence of
fever, IC mortality may be higher than in patients with fever or pyrexia
[33,43].
In this clinical setting, signs and symptoms of infectionsmay bemild
or absent, and detecting IC presents a difﬁcult albeit necessary task.
Considering that up to 50% of IC diagnoses are estimated to be missed,
attending physicians need a high index of suspicion to hasten microbi-
ological diagnosis and manage these potentially severe infections [44].
The search for the source of infection does not differ from good practice
in any clinical setting [45]; however, issues speciﬁc to early diagnosis or
exclusion of IC (pivotal from a clinical as well as from an antimicrobial
stewardship perspective) involve proper microbiological diagnosis,
with proper blood culturing in all cases. More advanced diagnostic
techniques (e.g., fungal antigen testing) might be reserved to high-risk
patients, and centralized in referral microbiology facilities [46–49].
In order to hasten microbiological diagnosis, blood cultures from an
arterial line might reduce the time to conﬁrmation of candidiasis espe-
cially in patients with few symptoms [50]. Source identiﬁcation and
control are necessary in patients with severe sepsis. This may require
CVC removal, as well as consultations in surgery (general, heart or vas-
cular as clinically appropriate), radiology, intensive care and infectious
diseases. In particular, removal of all potentially infected devices is piv-
otal, as there is strong evidence supporting improved outcomes with
CVC removal in patients with IC [32,38,51,52].
The stable patient with low risk of IC has no need of aggressive
management or treatment; on the other hand, an empirical antifungal
treatment can be considered in patients with ≥2 risk factors, pending
blood culture results, and according to clinical judgment; in this case
ﬂuconazole is an appropriate choice [9]. In severely ill patients at high
risk for IC, it is widely accepted that ﬁrst-line therapy should be an
echinocandin [11,53]. The actual choice of molecule within the
echinocandin class should be based on approved indications, personal
experience, known side effects, PK/PD parameters and evidence.
However, to reduce costs and limit impact on local resistance patterns,
de-escalation from echinocandins to ﬂuconazole is advisable when thepatient is stable, especially if the isolated Candida strain is ﬂuconazole-
susceptible [54,55]. The correct timing of de-escalation is still matter
of debate; the panel recommends reassessment at 72/96 h [24,56].
Echinocandins are the drug of choice when the diagnosis of IC is con-
ﬁrmed, independent of clinical severity. Once again, de-escalation is
an appropriate management strategy [53,54]. The overall duration of
therapy is not established, but there is consensus that treatment should
be continued until blood cultures are repeatedly negative; pursuing
both clinical and microbiological cure is critical to reducing the risk of
relapse.
4.3. Limitations
We acknowledge a number of limitations in this project. First, al-
though risk factor selectionwas based on an extensive literature review,
the list of risk factors is arbitrary; currently, it is not possible to assign
relative weights to individual risk factors. Also, implicit in the RAND/
UCLA method, most recommendations are derived from evidence ob-
tained in other settings or from expert opinion.
4.4. Conclusions
Applying the correct diagnostic and therapeutic approaches to IC in
the medical setting would greatly improve clinical outcomes and ad-
vance hospital cost-containment strategies [15,16]. One aimof this Con-
sensus is to raise awareness in internal medicine wards, where the risk
of IC risk is increasing. Another important issue is to optimize the use of
new microbiological diagnostic techniques, because early diagnosis
with prompt initiation of antifungal treatment can improve survival
[5,57]. We propose two algorithms for this purpose, developed to pro-
vide hospital managers and the physicians caring for medical patients
with a simple but comprehensive tool to support decision-making
around the issue of IC. We believe our proposed algorithms can be
adapted to different hospitals and settings.
Learning points
• Candida and IC are underestimated in general medical wards, but
there is increasing evidence of rising incidence
• Early diagnosis of IC with prompt and adequate treatment is associat-
ed with improved survival
• Patients with IC may have blunted inﬂammatory and febrile re-
sponses, therefore it is important to recognize these patients through
their risk factors, to facilitate the diagnosis of IC
• In all symptomatic patients, at least two blood cultures (one from a
CVC, if present) are mandatory to conﬁrm Candida infection
• High risk patients with severe sepsis are similar in severity to patients
admitted to ICUs, and therefore early antifungal treatment with an
echinocandin is recommended
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